ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

VTVT vTv Therapeutics Inc

27.72
-1.18 (-4.08%)
May 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 6,298
Bid Price 22.54
Ask Price 30.46
News -
Day High 28.84

Low
7.38

52 Week Range

High
39.60

Day Low 27.5419
Share Name Share Symbol Market Stock Type
vTv Therapeutics Inc VTVT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-1.18 -4.08% 27.72 16:16:17
Open Price Low Price High Price Close Price Previous Close
28.84 27.5419 28.84 27.72 28.90
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
324 6,298 US$ 28.13 US$ 177,148 - 7.38 - 39.60
Last Trade Type Quantity Price Currency
18:52:42 18 US$ 27.98 USD

vTv Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
83.44M 3.01M - 0 -20.25M -6.73 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

vTv Therapeutics News

Date Time Source News Article
5/09/202415:51GlobeNewswire Inc.vTv Therapeutics Announces 2024 First Quarter Financial..
5/09/202415:32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/09/202415:28Edgar (US Regulatory)Form 8-K - Current report
3/19/202407:30PR Newswire (US)CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA..
3/13/202407:00GlobeNewswire Inc.vTv Therapeutics Announces 2023 Fourth Quarter and Full Year..
3/07/202415:47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
3/05/202418:52Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial..
3/05/202407:04Edgar (US Regulatory)Form 8-K - Current report
3/04/202407:00GlobeNewswire Inc.vTv Therapeutics Announces FDA Submission for First Phase 3..
3/01/202407:00GlobeNewswire Inc.vTv Therapeutics to Participate at the TD Cowen 44th Annual..
2/28/202408:26Edgar (US Regulatory)Form 8-K - Current report
2/28/202408:14Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VTVT Message Board. Create One! See More Posts on VTVT Message Board See More Message Board Posts

Historical VTVT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week27.8829.0125.5028.526,272-0.16-0.57%
1 Month25.8929.1922.500126.285,5281.837.07%
3 Months17.1730.9912.9521.2313,42810.5561.44%
6 Months10.5130.997.3815.6449,29517.21163.75%
1 Year38.55639.607.3824.19105,723-10.84-28.10%
3 Years98.80115.207.3859.77441,955-71.08-71.94%
5 Years70.00205.207.3898.22931,808-42.28-60.40%

vTv Therapeutics Description

vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.